Literature DB >> 2559330

Fungispecificity of fluconazole against Candida albicans.

R H Liss1, R J Letourneau.   

Abstract

Candida albicans is an opportunistic pathogen of human mucosal surfaces. Colonization of oral and vaginal mucosa by this yeast is antagonized by the resident normal bacterial population. However, antibacterial therapy can alter the normal flora to allow fungal cells to attach, grow and invade host tissues. We studied the antimicrobic activity of fluconazole against clinical isolates of oral and vaginal bacteria and Candida albicans in vitro and in vivo by scanning and transmission electron microscopy; we also compared the bactericidal activity of fluconazole with clotrimazole in vitro by microbiologic assay. Fluconazole lysed fungi but did not change the ultrastructure of bacteria. Clotrimazole, but not fluconazole, was bactericidal against lactobacillus and streptococcus, the principal species of the oral and vaginal cavities. We conclude that Candida albicans, but not oral and vaginal bacteria, is susceptible to fluconazole. These observations help explain the antimycotic specificity of fluconazole and its efficacy against candidiasis in humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559330     DOI: 10.1007/BF00436222

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  23 in total

1.  Obfuscation of the activity of antifungal antimicrobics by culture media.

Authors:  P D Hoeprich; P D Finn
Journal:  J Infect Dis       Date:  1972-10       Impact factor: 5.226

Review 2.  Vaginal infection.

Authors:  D A Eschenbach
Journal:  Clin Obstet Gynecol       Date:  1983-03       Impact factor: 2.190

Review 3.  Host defences and the vaginal mucosa. A re-evaluation.

Authors:  M S Cohen; J R Black; R A Proctor; P F Sparling
Journal:  Scand J Urol Nephrol Suppl       Date:  1984

4.  The adhesion of the yeast Candida albicans to epithelial cells of human origin in vitro.

Authors:  L P Samaranayake; T W MacFarlane
Journal:  Arch Oral Biol       Date:  1981       Impact factor: 2.633

5.  Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.

Authors:  P F Troke; R J Andrews; K W Brammer; M S Marriott; K Richardson
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 6.  Ecology and epidemiology of Candida species.

Authors:  F C Odds
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1984-07

7.  Candida albicans ultrastructure: colonization and invasion of oral epithelium.

Authors:  J A Howlett; C A Squier
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

8.  Adherence of Candida albicans and other Candida species to mucosal epithelial cells.

Authors:  R D King; J C Lee; A L Morris
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

Review 9.  Vaginal microbial flora: practical and theoretic relevance.

Authors:  B Larsen; R P Galask
Journal:  Obstet Gynecol       Date:  1980-05       Impact factor: 7.661

Review 10.  Bacteriology of the vagina.

Authors:  G B Hill; D A Eschenbach; K K Holmes
Journal:  Scand J Urol Nephrol Suppl       Date:  1984
View more
  4 in total

1.  Fluconazole and platelet microbicidal protein inhibit Candida adherence to platelets in vitro.

Authors:  M R Yeaman; P M Sullam; P F Dazin; M A Ghannoum; J E Edwards; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

2.  Resistance to platelet microbicidal protein results in increased severity of experimental Candida albicans endocarditis.

Authors:  M R Yeaman; S S Soldan; M A Ghannoum; J E Edwards; S G Filler; A S Bayer
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

3.  Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B.

Authors:  M A Ghannoum; S G Filler; A S Ibrahim; Y Fu; J E Edwards
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

4.  Copper(II) and Zinc(II) Complexes with the Clinically Used Fluconazole: Comparison of Antifungal Activity and Therapeutic Potential.

Authors:  Nevena Lj Stevanović; Ivana Aleksic; Jakob Kljun; Sanja Skaro Bogojevic; Aleksandar Veselinovic; Jasmina Nikodinovic-Runic; Iztok Turel; Miloš I Djuran; Biljana Đ Glišić
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.